ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

House Measure Would Eliminate AHRQ, Rescind PCORI, Cut Outcomes Research, And Halt NIH’s Title 42 Hiring Program

July 20, 2012

Requiring Survival Data Was Logical In 1950s, Not Today, Broder Says

January 13, 1989

Army Will Outspend NCI In Breast Cancer In FY93, But How To Apply For a Grant?

October 16, 1992

Mammography Hazard In ACS-NCI Screening Charged

October 17, 1975

NCAB Asks Speedup Of OSP Coordinating Center Review

October 14, 1983

Fewer Side Effects With IMRT Than Traditional Radiation

August 31, 2007